On August 19, 2021, the Dental and Pharmaceutical Benefits Agency (TLV) has announced the withdrawal of two following assessments:
- MammaPrint test, upon the decision of the Medical Technology Product Council (reason not disclosed);
- EndoPredict test, as the manufacturer (Myriad Genetics) chose to refrain from participating in the health economic evaluation.
Earlier this year, the assessment was conducted for Oncotype and Prosigna tests as well. These assessments were accomplished, and the reports were released by TLV in July 2021.
The full details in Swedish can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.